Magenta Therapeutics is a clinical-stage biotechnology company. Co.'s primary targeted conditioning program, MGTA-117, has entered clinical development, and its second program, a CD45-antibody drug conjugate, is advancing in preclinical development. In addition, Co. is developing a product candidate, MGTA-145, to improve the process by which stem cells are stimulated out of the bone marrow and into the bloodstream so they are available for collection for future reinfusion, known as mobilization, which is required for transplants and gene therapy applications. MGTA-145 is a clinical stage program intended to enable mobilization and collection of functional stem cells for transplant. The MGTA stock yearly return is shown above.
The yearly return on the MGTA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MGTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|